Abstract:Influenza viruses evolve rapidly, driving seasonal epidemics and posing global pandemic threats. While neuraminidase (NA) has emerged as a vaccine target, shared molecular features of NA antibody responses are still not well understood. Here, we describe cryo-electron microscopy structures of the broadly protective human antibody DA03E17, which was previously identified from an H1N1-infected donor, in complex with NA from A/H1N1, A/H3N2, and B/Victoria-lineage viruses. DA03E17 targets the highly conserved NA active site using its long CDR H3, which features a DR (Asp-Arg) motif that engages catalytic residues and mimics sialic acid interactions. We further demonstrate that this motif is conserved among several NA active site-targeting antibodies, indicating a common receptor mimicry strategy. We also identified potential antibody precursors containing this DR motif in all donors of a healthy human donor BCR database, highlighting the prevalence of this motif and its potential as vaccine targeting. Our findings reveal shared molecular features in NA active site-targeting antibodies, offering insights for NA-based universal influenza vaccine design.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: how to design a broadly - protective influenza vaccine by targeting the active site of neuraminidase (NA). Specifically, the researchers aim to reveal how the human antibody DA03E17 interacts with the NA active site through the DR (Asp - Arg) motif in its complementarity - determining region H3 (CDR H3), thereby achieving broad protection against multiple influenza virus strains. ### Analysis of the Main Problem 1. **Rapid Evolution of Influenza Viruses**: Influenza viruses are highly variable, leading to the threat of seasonal epidemics and global pandemics. Existing influenza vaccines mainly induce antibody responses against hemagglutinin (HA), but due to the rapid antigenic drift of HA, these vaccines are often unable to effectively prevent infection and need to be updated annually. 2. **Neuraminidase (NA) as a Vaccine Target**: Neuraminidase is another glycoprotein on the surface of influenza viruses and is responsible for cleaving sialic acid from the surface of host cells, promoting the release of progeny viruses. Since the antigenic drift of NA is slower and independent of HA, it has become a potential target for developing broadly - protective influenza vaccines. 3. **Identifying the Molecular Characteristics of Broadly - Protective Antibodies**: In order to design effective immunogens, researchers need to identify the common molecular characteristics of antibodies that can protect different individuals broadly. In particular, those antibodies that can target the NA active site are of great interest because of their conservation and extensive cross - reactivity. ### Research Focus on the DA03E17 Antibody - **Structural Basis**: Using cryo - electron microscopy (cryo - EM) technology, the researchers resolved the structures of the DA03E17 antibody in complex with NAs from A/H1N1, A/H3N2, and B/Victoria - lineage viruses. The results showed that DA03E17 binds to the NA active site through its long CDR H3 region, where the DR motif mimics the sialic acid receptor interaction. - **Extensive Cross - Reactivity**: DA03E17 not only shows extensive cross - reactivity against multiple influenza virus strains but also can inhibit the sialidase activity of NA and provide protection against multiple subtypes of influenza viruses in vivo. - **Adaptation to N - Glycosylation Changes**: The study also found that although recent H3N2 virus strains have introduced N - glycosylation at the N245 site on NA, affecting the efficacy of some NA active site - targeting antibodies, DA03E17 can still maintain effective binding to the NA active site by inducing conformational changes in the N245 and N146 glycans. - **Universality of the DR Motif**: The researchers found similar DR or RD motifs in multiple NA active site - targeting antibodies, indicating that this motif has sequence and structural convergence in the antibody response, providing important clues for designing a universal influenza vaccine based on NA. In conclusion, this paper provides important structural and functional insights for developing a broadly - protective influenza vaccine by revealing the interaction mechanism between the DA03E17 antibody and the NA active site.

Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes

Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus

A human monoclonal antibody targeting the monomeric N6 neuraminidase confers protection against avian H5N6 influenza virus infection

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies

Structural Insights for Anti-Influenza Vaccine Design

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase

The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages

Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody FLD21.140

Structural Insight into a Human Neutralizing Antibody Against Influenza Virus H7N9.

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target